Similar articles

• The future of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma in the era of target-specific therapy.

  Ueno NT, Cheng YC. Ueno NT, et al. Bone Marrow Transplant. 2006 Dec;38(11):711-4. doi: 10.1038/sj.bmt.1705523. Bone Marrow Transplant. 2006. PMID: 17106451 No abstract available.
• Rapamycin-induced proteinuria following allogeneic hematopoietic stem cell transplantation.

  Hochegger K, Wurz E, Nachbaur D, Rosenkranz AR, Clausen J. Hochegger K, et al. Bone Marrow Transplant. 2009 Jul;44(1):63-5. doi: 10.1038/bmt.2008.433. Epub 2009 Jan 19. Bone Marrow Transplant. 2009. PMID: 19151795 No abstract available.
• Emerging drugs for acute graft-versus-host disease.

  Khaled Y, Reddy P, Krijanovski O. Khaled Y, et al. Expert Opin Emerg Drugs. 2009 Jun;14(2):219-32. doi: 10.1517/14728210903018891. Expert Opin Emerg Drugs. 2009. PMID: 19519285 Review.
• Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor.

  Eto M, Kamiryo Y, Takeuchi A, Harano M, Tatsugami K, Harada M, Kiyoshima K, Hamaguchi M, Teshima T, Tsuneyoshi M, Yoshikai Y, Naito S. Eto M, et al. Clin Cancer Res. 2008 May 1;14(9):2833-40. doi: 10.1158/1078-0432.CCR-07-1742. Clin Cancer Res. 2008. PMID: 18451251
• What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma.

  Ueno NT, Childs RW. Ueno NT, et al. Biol Blood Marrow Transplant. 2007 Jan;13(1):31-3. doi: 10.1016/j.bbmt.2006.09.011. Biol Blood Marrow Transplant. 2007. PMID: 17222750 Review. No abstract available.